Aprea Therapeutics advances APR-1051 oncology pipeline progress
I'm LongbridgeAI, I can summarize articles.Aprea Therapeutics reported Q2 2026 results, highlighting progress in its oncology pipeline led by WEE1 inhibitor APR-1051. The company accelerated enrollment in the ACESOT-1051 Phase 1 trial and presented early activity data at ASCO 2026. Aprea also paused monotherapy development of ATRN-119 to explore combination strategies. Financially, cash reserves rose to $41.2 million following a $30 million private placement, covering operations into Q1 2028 despite quarterly losses.
Claim 55% Off TipRanks
- Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions
- Subscribe to TipRanks Smart Investor Newsletter, and discover new investing opportunities with data-backed stock picks
Aprea Therapeutics ( (APRE) ) has shared an announcement.
On August 12, 2026, Aprea Therapeutics reported second-quarter 2026 results and detailed progress across its oncology pipeline, led by WEE1 inhibitor APR-1051. The company is accelerating enrollment in the ACESOT-1051 Phase 1 trial, expanding from three to ten sites and targeting 6 to 10 patients per month, with plans to enroll at least 50 patients with uterine serous carcinoma or Cyclin E–overexpressing platinum-resistant ovarian cancer.
Updated Phase 1 data presented at ASCO 2026 showed early single-agent activity for APR-1051, including partial responses and disease stabilization, with a manageable tolerability profile. Aprea also outlined plans to test APR-1051 in combination with immune checkpoint therapy in HPV-positive head and neck cancer and with chemotherapy in colorectal cancer, positioning the drug for broader use in biomarker-defined solid tumors.
The company has paused further monotherapy development of ATR inhibitor ATRN-119 after establishing a recommended Phase 2 dose in 2025, and is instead exploring combination strategies via discussions with leading academic centers. Potential investigator-initiated studies would assess ATRN-119 with immuno-oncology agents, chemotherapy, antibody-drug conjugates and radiation in advanced solid tumors and hematologic malignancies.
Financially, Aprea closed the June 30, 2026 quarter with $41.2 million in cash and cash equivalents, up from $14.6 million at year-end 2025, aided by a $30 million private placement earlier in 2026. The company posted a $4.0 million operating loss and a $3.6 million net loss for the quarter, and believes its current cash runway will fund operations and capital needs into the first quarter of 2028, supporting ongoing clinical expansion and pipeline development.
The most recent analyst rating on (APRE) stock is a Buy
with a $1.20 price target.
To see the full list of analyst forecasts on Aprea Therapeutics stock,
see the APRE Stock Forecast page.
Spark’s Take on APRE Stock
According to Spark, TipRanks’ AI Analyst, APRE is a Neutral.
The score is held down primarily by weak financial performance (ongoing losses and cash burn) and bearish technicals (price below key moving averages with negative MACD). Corporate events provide some offset via fresh financing and reported clinical progress, but negative earnings and no dividend limit valuation support.
To see Spark’s full report on APRE stock,
click here.
More about Aprea Therapeutics
Aprea Therapeutics, Inc. is a clinical-stage precision medicine oncology company developing targeted therapies for biomarker-defined cancers. Its lead programs are APR-1051, an oral small-molecule WEE1 kinase inhibitor, and ATRN-119, a macrocyclic ATR inhibitor, aimed at solid tumors including ovarian, endometrial, colorectal and HPV-positive head and neck cancers.
The company’s approach exploits vulnerabilities created by cancer cell mutations to kill tumors while minimizing effects on healthy cells. This strategy is intended to address high unmet medical needs across multiple tumor types where patients often lack effective therapeutic options.
Aprea is listed on Nasdaq under the ticker APRE and operates from Doylestown, Pennsylvania. Its pipeline also includes an early-stage macrocyclic DYRK1A/B inhibitor program that may advance into IND-enabling studies, subject to resource availability.
Average Trading Volume: 98,861
Technical Sentiment Signal: Sell
Current Market Cap: $7.98M
For a thorough assessment of APRE stock, go to TipRanks’ Stock Analysis page.